Welcome Guest | Register / Login

Pharmaceuticals Market Research Reports

Sort By
Title Published Price Buy Now
The US Hip Reconstruction Market: Size, Trends and Forecasts (2021-2025 Edition)
By Daedal Research
Scope of the Report The report titled "The US Hip Reconstruction Market: Size, Trends and Forecasts (2021-2025 Edition)", provides an in depth analysis of the US hip reconstruction market by value, by procedure volume, by type, etc. The ...
Apr 2021 $ 850
Global Oral Insulin Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)
By Daedal Research
Scope of the Report The report titled “Global Oral Insulin Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)”, provides an in depth analysis of the global oral insulin ma...
Apr 2021 $ 900
Clinical Trials - A Scorecard for Clinical Trial Investigations in 2020
By GlobalData
Clinical Trials - A Scorecard for Clinical Trial Investigations in 2020 Summary The purpose of this report is to provide insight into the clinical trial landscape for 2020, an analyses of the main features of these trials, a...
Mar 2021 $ 695
Smart Pharma - Technology brings Unprecedented Opportunities
By GlobalData
Smart Pharma - Technology brings Unprecedented Opportunities Summary Increased R&D costs, regulatory hurdles, and the emergence of new diseases are enforcing pharmaceutical companies to rethink their aging business models. T...
Mar 2021 $ 1495
Transcatheter Aortic Valve Replacement (TAVR) Product Market in China 2021
By StrategyHelix
The transcatheter aortic valve replacement (TAVR) product market in China in terms of revenue is set to grow by US$ 2 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 44.2% during the forecast period, according to data and...
Mar 2021 $ 450
Embolization Coil Market in China 2021
By StrategyHelix
The embolization coil market in China in terms of revenue is set to grow by US$ 233 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 11.3% during the forecast period, according to data and analytics company StrategyHelix....
Mar 2021 $ 450
Prostate Cancer Drug Market in China 2021
By StrategyHelix
The prostate cancer drug market in China in terms of revenue is set to grow by US$ 3 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 27.7% during the forecast period, according to data and analytics company StrategyHelix....
Mar 2021 $ 450
Global Prostate Cancer Drug Market 2021
By StrategyHelix
The global prostate cancer drug market in terms of revenue is set to grow by US$ 11 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 10.5% during the forecast period, according to data and analytics company StrategyHelix....
Mar 2021 $ 450
Microsphere Agents Market in China 2021
By StrategyHelix
The microsphere agents market in China in terms of revenue is set to grow by US$ 1 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 17.3% during the forecast period, according to data and analytics company StrategyHelix....
Mar 2021 $ 450
Global Enoxaparin Finished Dose Market 2021
By StrategyHelix
The global enoxaparin finished dose market in terms of revenue is set to grow by US$ 1 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 5.9% during the forecast period, according to data and analytics company StrategyHelix...
Mar 2021 $ 450
Enoxaparin Finished Dose Market in China 2021
By StrategyHelix
The enoxaparin finished dose market in China in terms of revenue is set to grow by US$ 968 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 23.6% during the forecast period, according to data and analytics company Strategy...
Mar 2021 $ 450
Global Heparin API Market 2021
By StrategyHelix
The global heparin API market in terms of revenue is set to grow by US$ 1 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 6.5% during the forecast period, according to data and analytics company StrategyHelix. ...
Mar 2021 $ 450
Global Biologics CDMO (Contract Development and Manufacturing Organization) Market 2021
By StrategyHelix
The global biologics CDMO (contract development and manufacturing organization) market in terms of revenue is set to grow by US$ 22 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 20.3% during the forecast period, accordi...
Mar 2021 $ 450
Ophthalmic Drug Market in China 2021
By StrategyHelix
The ophthalmic drug market in China in terms of revenue is set to grow by US$ 6 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 17.9% during the forecast period, according to data and analytics company StrategyHelix....
Mar 2021 $ 450
Artificial Tears Market in China 2021
By StrategyHelix
The artificial tears market in China in terms of revenue is set to grow by US$ 514 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 13.2% during the forecast period, according to data and analytics company StrategyHelix....
Mar 2021 $ 450
Global Heparin Finished Dose Market 2021
By StrategyHelix
The global heparin finished dose market in terms of revenue is set to grow by US$ 2 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 5.3% during the forecast period, according to data and analytics company StrategyHelix....
Mar 2021 $ 450
Pharmaceutical R&D Expenditure Market in China 2021
By StrategyHelix
The pharmaceutical R&D expenditure market in China in terms of revenue is set to grow by US$ 34 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 16.8% during the forecast period, according to data and analytics company Str...
Mar 2021 $ 450
Multi-Drug Resistance (MDR) Antibiotics Market in China 2021
By StrategyHelix
The multi-drug resistance (MDR) antibiotics market in China in terms of revenue is set to grow by US$ 3 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 9.7% during the forecast period, according to data and analytics comp...
Mar 2021 $ 450
Pulmonary Arterial Hypertension (PAH) Market in China 2021
By StrategyHelix
The pulmonary arterial hypertension (PAH) market in China in terms of revenue is set to grow by US$ 787 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 49.6% during the forecast period, according to data and analytics com...
Mar 2021 $ 450
Ulcerative Colitis (UC) Market in China 2021
By StrategyHelix
The ulcerative colitis (UC) market in China in terms of revenue is set to grow by US$ 1 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 16.5% during the forecast period, according to data and analytics company StrategyHel...
Mar 2021 $ 450
Central Nervous System Pharmaceutical Market in China 2021
By StrategyHelix
The central nervous system pharmaceutical market in China in terms of revenue is set to grow by US$ 10 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 4.6% during the forecast period, according to data and analytics compa...
Mar 2021 $ 450
Pemetrexed Pharmaceutical Market in China 2021
By StrategyHelix
The pemetrexed pharmaceutical market in China in terms of revenue is set to grow by US$ 443 million during 2021-2027, growing at a compound annual growth rate (CAGR) of 10.1% during the forecast period, according to data and analytics company Strateg...
Mar 2021 $ 450
Autoimmune Pharmaceutical Market in China 2021
By StrategyHelix
The autoimmune pharmaceutical market in China in terms of revenue is set to grow by US$ 12 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 26.6% during the forecast period, according to data and analytics company Strategy...
Mar 2021 $ 450
Edaravone Pharmaceutical Market in China 2021
By StrategyHelix
The edaravone pharmaceutical market in China in terms of revenue is expected to decline at a compound annual growth rate (CAGR) of -0.8% from US$ 426 million in 2020 to 429 million in 2027, according to data and analytics company StrategyHelix....
Mar 2021 $ 450
Biological Pharmaceuticals for Autoimmune Diseases Market in China 2021
By StrategyHelix
The biological pharmaceuticals for autoimmune diseases market in China in terms of revenue is set to grow by US$ 9 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 42.2% during the forecast period, according to data and an...
Mar 2021 $ 450
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy